Nanobiotechnology-based blood substitutes and the cardiovascular systems in transfusion medicine

Nanomedicine and the Cardiovascular System

Volumn , Issue , 2011, Pages 77-98

  Swi Chang, Thomas Ming ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; BLOOD; CYTOLOGY; ENZYMES; NANOBIOTECHNOLOGY; OXYGEN; VIRUSES;

ANTIOXIDANT ENZYME; BLOOD GROUP ANTIGEN; CLINICAL CONDITIONS; EMERGENCY SITUATION; GENERATION TYPES; HEPATITIS VIRUS; SUPER OXIDE DISMUTASE; TRANSFUSION MEDICINES;

CELLS;

EID: 84971601756     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (34)

1. Alayash, A.I., F. D’Agnillo and P.W. Buehler. 2007. First-generation blood substitutes: what have we learned? Biochemical and physiological perspectives. Expert Opin. Biol. Ther. 7: 665-675.
2. Atoji, T., M. Aihara, H. Sakai, E. Tsuchida and S. Takeoka. 2006. Hemoglobin vesicles containing methemoglobin and tyrosine to suppress methemoglobin formation in vitro and in vivo. Bioconjugate Chem. 17: 1241-1245.
3. Buehler, P.W., C.R. Haney, A. Gulati, L. Ma and C.J. Hsia. 2004. Polynitroxyl hemoglobin: a pharmacokinetic study of covalently bound nitroxides to hemoglobin platforms. Free Radical Biol. Med. 37: 124-135.
4. Chang, E.J., T.H. Lee and K. Mun. 2004. Effects of polyhemoglobin-antioxidant enzyme complex on ischemia-reperfusion in kidney. Transplant Proc. 36: 1952-1954.
5. Chang, T.M.S. 1957. “Hemoglobin Corpuscles” Honours Physiology Research Report, 1957, Medical Library, McGill University.
6. Chang, T.M.S. 1964. Semipermeable microcapsules. Science 146: 524.
7. Chang, T.M.S. 1971. Stabilisation of enzymes by microencapsulation with aconcentrated protein solution or by microencapsulation followed by cross-linking with glutaraldehyde. Biochem. Biophys. Res. Common. 44: 1531-1536.
8. Chang, T.M.S. 1972. Artificial cells. Monograph. Charles C Thomas, Springfield, IL (full text available with free access at www.artcell.mcgill.ca).
9. Chang, T.M.S. 1976. Biodegradable semipermeable microcapsules containing enzymes, hormones, vaccines, and other biologicals. J Bioeng. 1: 25-32.
10. Chang, T.M.S. 1997. Monograph. Red blood cell substitutes: Principles, Methods, Products and Clinical Trials Vol I Karger/Landes Systems, Basel, Switzerland (free access on www.artcell.mcgill.ca).
11. Chang, T.M.S., D. Powanda and W.P. Yu. 2003. Ultrathin polyethylene-glycol-polylactide copolymer membrane nanocapsules containing polymerized Hb and enzymes as nanodimension RBC substitutes. Artificial Cells, Blood Substitutes and Biotechnology 31: 231-248.
12. Chang, T.M.S. 2005. Therapeutic applications of polymeric artificial cells. Nature Review: Drug Discovery 4: 221-235.
13. Chang, T.M.S. 2007. Monograph on “ARTIFICIAL CELLS: Biotechnology, nanotechnology, blood substitutes, regenerative medicine, bioencapsulation, cell/stem cell therapy” Singapore, World Science Publisher/Imperial College Press, pp. 1-452 (full text available with free access at www.artcell.mcgill.ca).
14. Chang, T.M.S. 2009. Nanobiotechnology for hemoglobin based blood substitutes. Critical Care Clinics 25: 373-382.
15. Chang, T.M.S. 2010c. Artificial Cells, Blood Substitutes and Nanomedicine. McGill University website www.artcell.mcgill.ca
16. Chang, T.M.S. 2010a. Blood replacement with engineered hemoglobin and hemoglobin nanocapsules. WIRE Nanomed. Nanobiotechnol. 2: 418-430.
17. Chang, T.M.S. 2010b. Editorial: Blood substitutes in 2010 Artificiall Cells. Blood Substitutes and Biotechnology 38: 1.
18. D’Agnillo, F., and T.M.S. Chang. 1998. PolyHb-superoxide dismutase. catalase as a blood substitute with antioxidant properties. Nature Biotechnol. 16: 667-671.
19. Djordjevich, L., and I.F. Miller. 1980. Synthetic erythrocytes from lipid encapsulated hemoglobin. Exp. Hematol. 8: 584.
20. Gould, S.A., et al. 2002. The life-sustaining capacity of human polymerized Hb when red cells might be unavailable. J. Am. Coll. Surg. 195: 445-452.
21. Jahr, J.S., C. Mackenzie, L.B. Pearce, A. Pitman and A.G. Greenburg. 2008. HBOC-201 as an alternative to blood transfusion: efficacy and safety evaluation in a multicenter phase III trial in elective orthopaedic surgery. J Trauma 64: 1484-1497.
22. Liu, Z.C., and T.M.S. Chang. 2008. Long term effects on the histology and function of livers and spleens in rats after 33% toploading of PEG-PLA-nano artificial red blood cells. Artificial Cells, Blood Substitutes and Biotechnology 36: 513-524.
23. Moore, E.E., F.A. Moore, T.C. Fabian, A.C. Bernard, G.J. Fulda, D.B. Hoyt, T.M. Duane, L.J. Weireter Jr., G.A. Gomez, M.D. Cipolle, G.H. Rodman Jr., M.A. Malangoni, G.A. Hides, L.A. Omert and S.A. Gould. 2009. Human polymerized hemoglobin for the treatment of hemorrhagic shock when blood is unavailable: The USA multicenter trial. J. Am. Coll. Surg. 208: 1-13.
24. Natanson, C., S.J. Kern, P. Lurie, S.M. Banks and S.M. Wolfe. 2008. Meta-analysis: risk of myocardial infarction and death: cell-free hemoglobin-based blood substitutes. JAMA 299: 2304-2312.
25. Olofsson, C., A. Torbjo, T. Johansson, S. Larsson, P. Nellga, S. Ponzer, B. Fagrell, R. Przybelski, P. Keipert, N. Winslow and R.M. Winslow. 2006. A multicenter clinical study of the safety and activity of maleimide-polyethylene glycol-modified hemoglobin (Hemospan®) in patients undergoing major orthopedic surgery. Anesthesiology 105: 1153-1163.
26. Perutz, M.F. 1989. Myoglobin and Hb: Role of distal residues in reactions with haem ligands. Trends Biochem. Sci. 14: 42-44.
27. Phillips, W.T., R.W. Klipper, V.D. Awasthi, A.S. Rudolph, R. Cliff, V. Kwasiborski and B.A. Goins. 1999. Polyethylene glyco-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. J. Pharm. Exp. Ther. 288: 665-670.
28. Powanda, D. and T.M.S. Chang. 2002. Cross-linked polyHb-superoxide dismutase-catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion Artificial Cells. Blood Substitutes and Biotechnology 30: 25-42.
29. Tsuchida, E., H. Sakai, H. Horinouchi and K. Kobayashi. 2006. Hemoglobin-vesicles as a transfusion alternative. Artificial Cells, Blood Substitutes and Biotechnology 34: 581-588.
30. Winslow, R.M. (ed.). 2006. Blood Substitutes. Academic Press, Amsterdam 1-548.
31. Wong, N., and T.M.S. Chang. 2007. Polyhemoglobin-fibrinogen: a novel blood substitutes with platelet-like activity for extreme hemodilution. Artificial Cells, Blood Substitutes and Biotechnology 35: 481-489.
32. Yu, B.L., Z.C. Liu and T.M.S. Chang. 2006. PolyHb with different percentage of tetrameric Hb and effects on vasoactivity and electrocardiogram. Artificial Cells, Blood Substitutes and Biotechnology 34: 159-175.
33. Yu, B., M.J. Raher, G.P. Volpato, K.D. Bloch, F. Ichinose and W.M. Zapol. 2008. Inhaled nitric oxide enables artificial blood transfusion without hypertension. Circulation 15(117): 1982-1990.
34. Yu, B., M. Shahid, E.M. Egorina, M.A. Sovershaev, M.J. Raher, C. Lei, M.X. Wu, K.D. Bloch and W.M. Zapol. 2010. Endothelial dysfunction enhances vasoconstriction due to scavenging of nitric oxide by a hemoglobin-based oxygen carrier. Anesthesiology 112: 586-594.